JNJ Stock Forecast & Price Target

Johnson & Johnson reported impressive second-quarter 2025 results, with Innovative Medicine revenues reaching $15.20 billion, surpassing consensus expectations and demonstrating a year-over-year adjusted operational growth of 2.4%. The company raised its fiscal year 2025 sales guidance to between $93.2 billion and $93.6 billion, primarily due to operational improvement and favorable currency fluctuations, which reflect strengthening market conditions. Additionally, management forecasts accelerated sales growth in the second half of 2025 and into 2026, suggesting a robust outlook for both revenue and bottom-line performance moving forward.

Johnson & Johnson's stock outlook is negatively impacted by declining sales in key segments, particularly in Orthopedics and Infectious Diseases, where significant year-over-year operational decreases were noted. The company's reliance on a pharmaceutical pipeline that faces challenges from impending patent expirations and lower expected revenues contributes to concerns about achieving more than $57 billion in revenue by 2025. Additionally, competitive pressures within the MedTech division and the potential for M&A integration disruptions raise further doubts about the company's ability to sustain growth and manage costs effectively.